PharmaLedger
Project information
PharmaLedger
Grant agreement ID: 853992
Status
Ongoing project
-
Start date
1 January 2020
-
End date
31 December 2022
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 20 920 901,75
-
EU contribution
€ 8 290 693,75
Project description
A digital boost for the healthcare industry
The internet and other digital advances are playing an increasingly bigger role in daily life by enabling industries to innovate, thus delivering improved services to both consumers and providers. Unfortunately, the healthcare industry hasn’t caught up as fast. The EU-funded PharmaLedger project will create and introduce a blockchain-based framework that will efficiently digitalise the healthcare industry and empower patients. It plans to do this by bringing together 29 partners including 10 EU member states, several large pharmaceutical companies and many other specialists in blockchain development, security, privacy and business intelligence. The goal of the project is to provide a widely trusted platform that will support the design and adoption of blockchain-enabled healthcare solutions while accelerating delivery of innovation that will benefit the entire ecosystem, from manufacturers to patients.
Field of Science
/social sciences/economics and business
/medical and health sciences/health sciences/health care services
/natural sciences/computer and information sciences/data science/big data
/natural sciences/computer and information sciences/data science/business intelligence
/natural sciences/computer and information sciences/artificial intelligence/machine learning
/natural sciences/computer and information sciences/data science/data analysis
Funding Scheme
IMI2-RIA - Research and Innovation action
Coordinator
UNIVERSIDAD POLITECNICA DE MADRID
Address
Calle Ramiro De Maeztu 7 Edificio Rectorado
28040 Madrid
Spain
Activity type
Higher or Secondary Education Establishments
EU Contribution
€ 873 750
Participants (27)
NOVARTIS PHARMA AG
Switzerland
PDM E FC PROJECTO DESENVOLVIMENTO MANUTENCAO FORMACAO E CONSULTADORIALDA
Portugal
EU Contribution
€ 648 125
ROMSOFT SRL
Romania
EU Contribution
€ 1 157 500
ARTEEVO TECHNOLOGIES LTD
Israel
EU Contribution
€ 906 250
TECHNOVATIVE SOLUTIONS LTD
United Kingdom
EU Contribution
€ 910 625
EKON MODELING SOFWARE SYSTEMS LTD*EKON
Israel
EU Contribution
€ 456 250
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS
Greece
EU Contribution
€ 282 500
ABBVIE INC
United States
ASTRAZENECA AB
Sweden
BAYER AKTIENGESELLSCHAFT
Germany
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.
United Kingdom
JANSSEN PHARMACEUTICA NV
Belgium
MERCK SHARP & DOHME CORP
United States
NOVO NORDISK A/S
Denmark
PFIZER LIMITED
United Kingdom
F. HOFFMANN-LA ROCHE AG
Switzerland
UCB BIOPHARMA SRL
Belgium
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
EU Contribution
€ 338 500
ONORACH LTD
United Kingdom
EU Contribution
€ 511 568,75
NATIONAL RESEARCH AND DEVELOPMENT INSTITUTE FOR CRYOGENICS AND ISOTOPIC TECHNOLOGIES ICSI RM VALCEA
Romania
EU Contribution
€ 370 000
UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Germany
EU Contribution
€ 307 500
DIMOKRITIO PANEPISTIMIO THRAKIS
Greece
EU Contribution
€ 216 250
HOSPITAL DO ESPIRITO SANTO DE EVORA EPE
Portugal
EU Contribution
€ 351 250
OSPEDALE PEDIATRICO BAMBINO GESU
Italy
EU Contribution
€ 347 500
IMPRENSA NACIONAL - CASA DA MOEDA, S. A.
Portugal
EU Contribution
€ 365 625
FORUM EUROPEEN DES PATIENTS (FPE)
Luxembourg
EU Contribution
€ 143 750
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE
Belgium
EU Contribution
€ 103 750
Project information
PharmaLedger
Grant agreement ID: 853992
Status
Ongoing project
-
Start date
1 January 2020
-
End date
31 December 2022
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 20 920 901,75
-
EU contribution
€ 8 290 693,75
Project information
PharmaLedger
Grant agreement ID: 853992
Status
Ongoing project
-
Start date
1 January 2020
-
End date
31 December 2022
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 20 920 901,75
-
EU contribution
€ 8 290 693,75
Project information
PharmaLedger
Grant agreement ID: 853992
Status
Ongoing project
-
Start date
1 January 2020
-
End date
31 December 2022
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 20 920 901,75
-
EU contribution
€ 8 290 693,75
Project information
PharmaLedger
Grant agreement ID: 853992
Status
Ongoing project
-
Start date
1 January 2020
-
End date
31 December 2022
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 20 920 901,75
-
EU contribution
€ 8 290 693,75
Deliverables
Deliverables not available
Publications
Publications not available
Project information
PharmaLedger
Grant agreement ID: 853992
Status
Ongoing project
-
Start date
1 January 2020
-
End date
31 December 2022
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 20 920 901,75
-
EU contribution
€ 8 290 693,75
Project information
PharmaLedger
Grant agreement ID: 853992
Status
Ongoing project
-
Start date
1 January 2020
-
End date
31 December 2022
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 20 920 901,75
-
EU contribution
€ 8 290 693,75
Project information
PharmaLedger
Grant agreement ID: 853992
Status
Ongoing project
-
Start date
1 January 2020
-
End date
31 December 2022
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 20 920 901,75
-
EU contribution
€ 8 290 693,75
